Association of BRCA1 and BRCA2 Pathogenic Variants with Increased Risk of Cancer
Findings from the Consortium of Investigators of Modifiers of BRCA1/2 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease
Evidence for efficacy is based on the results from the GVHD-1 and GVHD-2 studies
Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in BRAF V600E–Mutated Anaplastic Thyroid Cancer
Findings from updated data analysis in the anaplastic thyroid cancer cohort from the ROAR basket study
Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated HER2-Mutated Metastatic NSCLC
Findings from a primary analysis of the DESTINY-Lung01 study in patients with non-small cell lung cancer
Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs
Activated CD4 memory T cell abundance and T cell receptor diversity are associated with development of severe immune-related adverse events
Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab Than with Chemotherapy in Advanced Endometrial Cancer
Findings from the Study 309–KEYNOTE-775 among patients who had disease progression after the receipt of previous systemic platinum-based therapy
A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival in Unselected Patients with mCRPC Whose Disease Progressed on Abiraterone
IMbassador 250 findings indicate that biology associated with response to immune checkpoint inhibition is present in few patients with metastatic castration-resistant prostate cancer
Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer
PANDA challenge consortium cohort report
Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers
Genetic subtyping more accurately reflects clinical behaviour than reliance on pathologic classification only
A Phase III Study of Spartalizumab in Combination with Dabrafenib and Trametinib Did Not Meet Primary Endpoint in BRAF V600–Mutated Metastatic Melanoma
Findings from the COMBI-I study
Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant OS Improvement in Patients with HER2-positive Metastatic Breast Cancer
Final overall survival analysis from the HER2CLIMB study
Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early Breast Cancer
Findings from the FinXX study